Daily News

Daily News

Fucoidan suppresses the gastric cancer cell malignant phenotype and production of TGF-b1

Genomics & Genetics Daily

2019 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Daily -- Investigators publish new report on Oncology - Gastric Cancer. According to news reporting originating from Shanghai, People’s Republic of China, by NewsRx correspondents, research stated, “The sulfated polysaccharide fucoidan displays excellent anticancer properties with low toxicity in many kinds of cancers. However, its detailed pharmacological effect and mechanism of action in gastric carcinoma remains unclear.”

Financial supporters for this research include National Natural Science Foundation of China, Shandong Provincial Key Laboratory of Glycoscience & Glycotechnology, The National Key Research and Development Program of China.

Our news editors obtained a quote from the research from the University of Fudan, “In this study, we found that fucoidan could suppress gastric cancer (GC) cell growth, as well as cell migration and invasion. A cytokine expression screen demonstrated that TGF-b1 secretion was decreased in fucoidan-treated cells. Fucoidan has been reported to be a platelet agonist for the C-type lectin-like receptor 2 (CLEC-2), and our previous research found that upregulation of CLEC-2 inhibited GC progression. Here, we confirmed that fucoidan, combined with CLEC-2, significantly increased CLEC-2 expression in GC cells via the transcription factor CDX2, an important regulator of gut homeostasis. In addition, the inhibitory effect of fucoidan on the gastric cancer cell malignant phenotype and TGF-b1 secretion could be restored by knocking down CLEC-2.”

According to the news editors, the research concluded: “Thus, our data suggest that fucoidan targets CLEC-2 to exert anti-tumorigenesis and anti-metastatic activity, suggesting that fucoidan is a promising treatment for gastric carcinoma.”

For more information on this research see: Fucoidan suppresses the gastric cancer cell malignant phenotype and production of TGF-b1 via CLEC-2. Glycobiology, 2019;():. (Oxford University Press - http://www.oup.com/; Glycobiology - glycob.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting L. Xu, Dept. of Biochemistry and Molecular Biology, School of Basic Medical Sciences, University of Fudan, Shanghai 200032, People’s Republic of China. Additional authors for this research include F. Liu, C. Li, S. Li, H. Wu, B. Guo, J. Gu and L. Wang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1093/glycob/cwz097. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)